Panacea Biotec Limited (PANACEABIO) Price & Analysis

Compare

0 Followers

PANACEABIO Stock Chart & Stats

₹358.50

-₹0.60(-0.13%)

At close: Jan 08 4:00 PM EST

₹358.50

-₹0.60(-0.13%)

Day’s Range― - ―

52-Week Range₹284.35 - ₹581.00

Previous CloseN/A

Volume134.82K

Average Volume (3M)12.44K

Market Cap

₹20.07B

Enterprise Value₹19.58B

Total Cash (Recent Filing)₹1.10B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)―

Beta1.70

Next Earnings

May 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.65

Shares Outstanding61,250,744

10 Day Avg. Volume14,140

30 Day Avg. Volume12,438

Financial Highlights & Ratios

PEG Ratio-0.53

Price to Book (P/B)3.31

Price to Sales (P/S)4.94

P/FCF Ratio-35.56

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthExtremely low leverage and a high equity ratio provide durable financial flexibility. This structure supports funding vaccine and biologics manufacturing, R&D or tender participation without immediate refinancing, helping the company absorb industry cycles and invest for medium-term growth.

High Gross MarginA ~64% gross margin signals strong product-level economics or favorable product mix (vaccines/biologics vs. commoditized generics). Sustained high gross margins can support recovery of operating profits, fund R&D, and provide pricing flexibility over the medium term.

Diversified Pharma & Vaccine ModelOperating across branded/generics, vaccines, biologics and manufacturing gives multiple durable revenue channels. Exposure to institutional vaccine tenders and contract manufacturing reduces single-product dependency and supports steadier demand over 2–6 months.

Bears Say

Weak Cash GenerationPersistent negative operating and free cash flow undermines the company’s ability to self-fund capex, scale vaccine capacity or support working capital. Over months this forces reliance on external financing or asset sales, reducing strategic optionality and increasing execution risk.

Ongoing Profitability LossesSustained negative EBIT and net losses weaken retained earnings and limit reinvestment into commercialization or R&D. Without a clear path to operating profitability, the business faces higher financing needs and constrained ability to compete for large institutional contracts long term.

Stagnant Revenue / Declining AssetsRevenue stagnation combined with reported declines in total assets and shareholders' equity signal a shrinking capacity to grow. Over months this can erode market position, limit manufacturing scale-up, and reduce the ROI on any incremental investment in vaccines or new formulations.

Panacea Biotec Limited News

Panacea Biotec Disputes ₹9.38 Crore Tax Penalty, Sees No Material Business Impact

Panacea Biotec Limited ( ($IN:PANACEABIO) ) has provided an announcement. Panacea Biotec Limited has disclosed that it has...

2M ago

Panacea Biotec Announces Leadership Changes and Policy Updates

Panacea Biotec Limited ( ($IN:PANACEABIO) ) has shared an announcement. Panacea Biotec Limited announced key changes in its...

3M ago

Panacea Biotec Announces 41st AGM Details and Compliance Measures

Panacea Biotec Limited ( ($IN:PANACEABIO) ) has shared an update. Panacea Biotec Limited announced the publication of a...

6M ago

Panacea Biotec Releases Q1 2025 Financial Results

Panacea Biotec Limited ( ($IN:PANACEABIO) ) has shared an announcement. Panacea Biotec Limited has published its unaudited standalone...

7M ago

Panacea Biotec Announces Director Change

Panacea Biotec Limited ( ($IN:PANACEABIO) ) has shared an update. Panacea Biotec Limited announced the completion of Mr....

11M ago

Panacea Biotec Announces Senior Management Change

Panacea Biotec Limited ( ($IN:PANACEABIO) ) just unveiled an update. Panacea Biotec Limited announced the superannuation of Mr....

11M ago

PANACEABIO FAQ

What was Panacea Biotec Limited’s price range in the past 12 months?

Panacea Biotec Limited lowest stock price was ₹284.35 and its highest was ₹581.00 in the past 12 months.

What is Panacea Biotec Limited’s market cap?

Panacea Biotec Limited’s market cap is ₹20.07B.

When is Panacea Biotec Limited’s upcoming earnings report date?

Panacea Biotec Limited’s upcoming earnings report date is May 28, 2026 which is in 86 days.

How were Panacea Biotec Limited’s earnings last quarter?

Panacea Biotec Limited released its earnings results on Feb 11, 2026. The company reported ₹0.65 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.65.

Is Panacea Biotec Limited overvalued?

According to Wall Street analysts Panacea Biotec Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Panacea Biotec Limited pay dividends?

Panacea Biotec Limited pays a Annually dividend of ₹0.75 which represents an annual dividend yield of N/A. See more information on Panacea Biotec Limited dividends here

What is Panacea Biotec Limited’s EPS estimate?

Panacea Biotec Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Panacea Biotec Limited have?

Panacea Biotec Limited has 61,250,744 shares outstanding.

What happened to Panacea Biotec Limited’s price movement after its last earnings report?

Panacea Biotec Limited reported an EPS of ₹0.65 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.399%.

Which hedge fund is a major shareholder of Panacea Biotec Limited?

Currently, no hedge funds are holding shares in IN:PANACEABIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Panacea Biotec Limited

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.